Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

被引：0
|
作者：
de Jesus, Cabrera-Lopez Teresita [1 ]
Edgar, Perez-Barragan [2 ]
Ruben, Nava-Campos Carlos [1 ]
Marla, Toiber-Rodriguez [3 ]
Carlos, Rodriguez-Aldama Juan [2 ]
Adrian, Cruz-Flores Raul [4 ]
Andrea, Gonzalez-Rodriguez [5 ]
机构：
[1] Clin Especializada Condesa Iztapalapa, Dept Gynecol & Care Victims Sexual Assault, Mexico City, Mexico
[2] Clin Especializada Condesa Iztapalapa, Dept Infect Dis, Combate Celaya 352, Mexico City 09730, Mexico
[3] Clin Especializada Condesa Iztapalapa, Dept Mental Hlth, Mexico City, Mexico
[4] Clin Especializada Condesa Iztapalapa, Dept Epidemiol, Mexico City, Mexico
[5] Clin Especializada Condesa, Mexico City, Mexico
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 08期
关键词：
bictegravir/emtricitabine/tenofovir alafenamide; HIV; INSTI; post-exposure prophylaxis; sexual assault; HIV; HEALTH; RECOMMENDATIONS; EXPOSURE;
D O I：
10.1093/ofid/ofae436
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
    Gan, Lin
    Xie, Xiaoxin
    Fu, Yanhua
    Yang, Xiaoyan
    Ma, Shujing
    Kong, Linghong
    Song, Chunli
    Song, Yebing
    Ren, Tingting
    Long, Hai
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (11) : 2581 - 2593
  • [22] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort
    Monforte, A. d'Arminio
    Tavelli, A.
    Cingolani, A.
    Taramasso, L.
    Mussini, C.
    Piconi, S.
    Calcagno, A.
    Orofino, G.
    Cicalini, S.
    Castagna, A.
    Ceccherini-Silberstein, F.
    Gori, A.
    Guaraldi, G.
    Antinori, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 98 - 99
  • [23] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BTC/FTC/TAF) in ART-naive patients: real-world data from the ICONA cohort
    Tavelli, A.
    Marchetti, G.
    Vergori, A.
    Quiros-Roldan, E.
    Malagnino, V.
    Vichi, F.
    Lichtner, M.
    Nozza, S.
    Rossotti, R.
    Sarmati, L.
    Bai, F.
    Di Biagio, A.
    Antinori, A.
    Monforte, A. d'Arminio
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 62 - 63
  • [24] Eficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing NRTI resistances: real world data
    Mican, R.
    Grela, A. de Gea
    Busca, C.
    Bernardino, J. I.
    Montejano, R.
    Montes, M.
    Cardinanos, J.
    de Miguel, R.
    Serrano, L.
    Perez-Valero, I.
    Valencia, E.
    Moreno, V.
    Arribas, J. R.
    Gonzalez-Garcia, J.
    Martin-Carbonero, L.
    HIV MEDICINE, 2021, 22 : 30 - 31
  • [25] Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of weight Gain in naive people living with HIV of Asian OrigiN (DRAGON study)
    Chen, Jang-Pin
    Chen, Tsung-Chia
    Hsih, Wen-Hsin
    Tsai, Mao-Song
    Yang, Chia-Jui
    Cheng, Shu-Hsing
    Lin, Yi-Chun
    Ma, Ping
    Zhao, Qingxia
    Zou, Meiyin
    Wu, Yi-Wen
    Huang, Miao-Hui
    Sheng, Wang-Huei
    Cheng, Chien-Yu
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 267 - 268
  • [26] The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide - Real-world data from the German IQVIA prescription database
    Umland, T.
    Stellbrink, H.
    Calvo, M.
    Zahn, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 88 - 90
  • [27] Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study
    Mata Marin, Jose Antonio
    Velasco-Penagos, Juan Carlos
    Mauss, Stefan
    Rodriguez-Evaristo, Mara Soraya
    Perez-Barragan, Edgar
    Villa-Platas, Joaquin
    Barragan-Huerta, Laura
    Gaytan-Martinez, Jesus Enrique
    INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (01) : 33 - 38
  • [28] Liver enzyme variation after switching to emtricitabine/tenofovir alafenamide/bictegravir is associated with glucose increase in a real-life cohort
    Squillace, N.
    Ricci, E.
    Maggi, P.
    Menzaghi, B.
    De Socio, G.
    Orofino, G.
    Celesia, B.
    Bandera, A.
    Salomoni, E.
    Di Biagio, A.
    Taramasso, L.
    Piconi, S.
    Sarchi, E.
    Valsecchi, L.
    Pellicano, G.
    Cenderello, G.
    Bonfanti, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 151 - 153
  • [29] Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV a 2/3,-label,-arm study
    Rodriguez, Carina A.
    Natukunda, Eva
    Strehlau, Renate
    Venter, Esme L.
    Rungmaitree, Supattra
    Cunningham, Coleen K.
    Lalloo, Umesh
    Kosalaraksa, Pope
    Hellstroem, Elizabeth
    Liberty, Afaaf
    Mcgrath, Eric J.
    Kaur, Meenu
    Leisegang, Rory
    Hindman, Jason
    Vieira, Vinicius A.
    Kersey, Kathryn
    Cotton, Mark F.
    Rakhmanina, Natella
    Gaur, Aditya H.
    LANCET HIV, 2024, 11 (05): : e300 - e308
  • [30] An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1
    Liu, An
    Xin, Ruolei
    Zhang, Hongwei
    Dai, Lili
    Wu, Ruojun
    Wang, Xi
    Li, Aixin
    Hua, Wei
    Li, Jianwei
    Shao, Ying
    Gao, Yue
    Wang, Zhangli
    Ye, Jiangzhu
    Ti, Gulimila A. Bu Dou Re Xi
    Li, Zaicun
    Sun, Lijun
    CHINESE MEDICAL JOURNAL, 2022, 135 (22) : 2725 - 2729
12345